Based on these results, sotorasib was granted accelerated approval by the US Food and Drug Administration in May of 2021 for adult patients with advanced KRAS G12C–mutant NSCLC who received at least one prior systemic therapy. This evidence concerns the gene KRAS and non-small cell lung carcinoma.